Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
![New England Journal of Medicine publishes phase 3 trial data demonstrating improvements in BMI and body weight in adolescents with obesity taking Saxenda® New England Journal of Medicine publishes phase 3 trial data demonstrating improvements in BMI and body weight in adolescents with obesity taking Saxenda®](https://mma.prnewswire.com/media/466582/Novo_Nordisk_Logo.jpg?p=twitter)
New England Journal of Medicine publishes phase 3 trial data demonstrating improvements in BMI and body weight in adolescents with obesity taking Saxenda®
![Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years — MedWatch Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years — MedWatch](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13178783.ece/ALTERNATES/schema-16_9/doc7gyc8khcpyo68mwe5bp.jpg)